Drug combination before standard treatment for locally advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a combination of three drugs (nab-paclitaxel, cisplatin, and sintilimab) given before standard treatment for locally advanced cervical cancer. The goal is to see if this 'neoadjuvant' approach can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a type of cervical cancer called squamous cell, adenocarcinoma, or adenosquamous carcinoma.
- Your cancer stage is IB3 or IIA2 (a specific early but locally advanced stage).
- You have not had any prior treatment for cervical cancer (like surgery, radiation, or chemo).
- Your overall health is good enough to be active and look after yourself (a score of 0-2 on a common scale).
- You are willing to use effective birth control or are past menopause.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs (immunotherapy plus a targeted pill plus chemo) versus a standard combo (immunotherapy plus chemo) before surgery, for people with stage IV stomach cancer. The goal is to see if this approach can shrink the cancer enough to make it removable, potentially improving outcomes.
This trial tests combining standard chemoradiation with a PD-1 inhibitor (a drug that helps your immune system fight cancer) for advanced cervical cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatment alone.
This trial tests a new combination of two immunotherapy drugs with standard chemotherapy before surgery for cervical cancer that has not spread far. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy before surgery for locally advanced cervical cancer. It aims to shrink tumors and improve outcomes for patients who haven't had prior systemic treatment.
This trial tests if giving the immunotherapy drug pembrolizumab before and after standard chemoradiation works better than the standard approach for people with high-risk cervical cancer that has spread locally.
This trial tests a combination of three drugs before standard treatment for locally advanced cervical cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
Hear when a new Cervical Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.